Alliance Pharma plc provided earnings guidance for the second half of 2023. For the period, The company anticipates strong growth in H2 as Kelo-Cote revenues continue to build, the company recommence supply of products that have been out of stock and launch new product innovation. The Board's expectation for Group year-end performance remains unchanged.